Aspirinlow Dose
Product Images NDC 70882-122

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aspirinlow Dose (NDC 70882-122). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cambridge Therapeutics Technologies, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clopiodgrel-01 (Clopidogrel Tablets Usp Apotex 1)

Chemical structure diagram of the active ingredient in AspirinLow Dose Low Dose by Cambridge Therapeutics Technologies, LLC, showing the molecular composition including carbon, hydrogen, chlorine, sulfur, nitrogen atoms, and associated functional groups along with sulfuric acid (H2SO4).*

FDA Label Image

Figure8.jpg (Clopidogrel Tablets Usp Apotex 10)

A forest plot showing hazard ratios and 95% confidence intervals comparing Clopidogrel and Aspirin across baseline subgroups in the CAPRIE study. Subgroups include Stroke, MI, PAD, and Overall. The x-axis represents hazard ratios from 0.6 to 1.3, where values left favor Clopidogrel and right favor Aspirin.*

FDA Label Image

Clopidogrel Tablets, Usp 75mg (Clopidogrel Tablets Usp Apotex 11)

Packaging label for Clopidogrel Kit showing the product name 'Clopidogrel Kit' prominently on multiple panels and including the NDC 70882-123-01. The label has barcode information and storage instruction note to 'See package insert for storage conditions.' No active ingredient strength or manufacturer name is visible on this label.*

FDA Label Image

Figure-01 (Clopidogrel Tablets Usp Apotex 2)

A horizontal error bar chart illustrating the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite exposure of Clopidogrel 75 mg. The chart compares Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, showing their relative change in active metabolite AUC with 90% confidence intervals, relative to Clopidogrel administered alone.*

FDA Label Image

Figure2 (Clopidogrel Tablets Usp Apotex 3)

A line chart titled 'Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study' showing cumulative event rate (%) over 12 months of follow-up. It compares two groups: one receiving placebo plus aspirin and the other receiving clopidogrel plus aspirin, illustrating lower event rates in the clopidogrel plus aspirin group. The graph includes a significance value (P=0.00009) and notes that other standard therapies were used as appropriate.*

FDA Label Image

Figure3.jpg (Clopidogrel Tablets Usp Apotex 4)

A forest plot chart titled 'Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study.' It compares subgroups, including age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke, showing hazard ratios with confidence intervals favoring Clopidogrel or placebo. The x-axis represents hazard ratios from 0.3 to 1.4, with markers and intervals for each subgroup along with sample sizes and event counts for Clopidogrel and placebo groups.*

FDA Label Image

Figure3b.jpg (Clopidogrel Tablets Usp Apotex 5)

A figure presenting the hazard ratio with 95% confidence intervals for patient baseline characteristics and on-study concomitant medications or interventions in the CURE study. Subgroups include Heparin/LMWH usage, aspirin doses, GPIIb/IIIa antagonist usage, beta-blocker usage, and ACE inhibitor usage. The chart compares Clopidogrel to placebo across these subgroups.*

FDA Label Image

Figure4 (Clopidogrel Tablets Usp Apotex 6)

A line chart titled 'Cumulative Event Rates for Death in the COMMIT Study' showing the percentage dead before first discharge over days since randomization (up to 28 days). The graph compares death rates between placebo and clopidogrel groups, with labeled death counts and percentages for each.*

FDA Label Image

Figure5 (Clopidogrel Tablets Usp Apotex 7)

A line graph showing cumulative event rates for the combined endpoint of re-infarction, stroke, or death over 28 days in the COMMIT study. The y-axis represents the percentage with events before discharge, and the x-axis shows days since randomization. Two lines compare placebo and clopidogrel groups, indicating event rates of 10.1% and 9.2%, respectively.*

FDA Label Image

Figure6.jpg (Clopidogrel Tablets Usp Apotex 8)

A forest plot from the COMMIT Study displaying the effects of adding Clopidogrel to Aspirin on the combined primary endpoint across various subgroups. The plot compares odds ratios with confidence intervals for Clopidogrel vs. placebo, categorized by gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent usage.*

FDA Label Image

Figure7.jpg (Clopidogrel Tablets Usp Apotex 9)

A line graph depicting the cumulative event rate (%) of fatal or non-fatal vascular events over months of follow-up (0 to 36) in the CAPRIE study. Two curves represent the event rates for Aspirin and Clopidogrel, with Clopidogrel showing a slightly lower rate over time. A significance value (P=0.045) is noted on the graph.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.